A double-blind, placebo controlled, phase I study to assess safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of GIC-1001 in normal healthy volunteers

Trial Profile

A double-blind, placebo controlled, phase I study to assess safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of GIC-1001 in normal healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2017

At a glance

  • Drugs Trimebutine 3-thiocarbamoylbenzenesulfonate (Primary)
  • Indications Procedural pain
  • Focus Adverse reactions
  • Sponsors gIcare Pharma
  • Most Recent Events

    • 22 Mar 2014 Multiple ascending dose results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 22 Mar 2014 Single ascending dose results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 08 Mar 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top